Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in Radiother Oncol Retrieve available abstracts of 96 articles: HTML format

Single Articles

September 2026
1. VISANI L, Becherini C, Kubeczko M, Caini S, et al
   Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis.
   Radiother Oncol. 2026 Sep 30:111800. doi: 10.1016/j.radonc.2026.111800.
   PubMed     Abstract available
   
   
   
2. VIANI GA, Hamamura AC, Arruda CV, Cardoso CE, et al
   Stereotactic ablative radiotherapy for oligometastatic breast cancer: A systematic review and meta-analysis (SABRINA).
   Radiother Oncol. 2026 Sep 20:111789. doi: 10.1016/j.radonc.2026.111789.
   PubMed     Abstract available
   
   
   
3. CATALANO A, Materne S, Badenchini F, Gioscio E, et al
   Microvascular health status as a novel predictor of acute side effects after radiotherapy: a quantitative analysis across three cancer sites.
   Radiother Oncol. 2026;222:111693.
   PubMed     Abstract available
   
   
   August 2026
4. VIANI GA, Arruda CV, Hamamura AC, Cardoso CE, et al
   Preoperative stereotactic body radiotherapy for early-stage luminal breast cancer: a systematic review and meta-analysis (PRELUMEN).
   Radiother Oncol. 2026 Aug 15:111743. doi: 10.1016/j.radonc.2026.111743.
   PubMed     Abstract available
   
   
   
5. HONG SW, Kim EK, Shin HC, Beom J, et al
   Dosimetric parameters of the axillary-lateral thoracic junction in predicting risk of breast cancer-related lymphedema.
   Radiother Oncol. 2026 Aug 13:111725. doi: 10.1016/j.radonc.2026.111725.
   PubMed     Abstract available
   
   
   July 2026
6. CHAN J, Knight A, Baker L, Metz G, et al
   Dosimetry and toxicity outcomes of knowledge-based volumetric modulated arc therapy for breast cancer: A retrospective cohort analysis.
   Radiother Oncol. 2026 Jul 17:111704. doi: 10.1016/j.radonc.2026.111704.
   PubMed     Abstract available
   
   
   
7. CHAKRABORTY S, Chatterjee S, S P, Lal P, et al
   Impact of ultrahypofractionated adjuvant regional nodal radiotherapy on patient-reported quality of life: the HYPORT adjuvant trial (NCT03788213).
   Radiother Oncol. 2026;220:111576.
   PubMed     Abstract available
   
   
   
8. SHAITELMAN SF, Krishnamurthy S, Rauch GM, Lin H, et al
   Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial.
   Radiother Oncol. 2026;220:111573.
   PubMed     Abstract available
   
   
   
9. LEMANSKI C, Houvenaeghel G, Gourgou S, Gutowski M, et al
   Feasibility and safety of repeat breast-conserving surgery with intraoperative irradiation for local breast carcinoma recurrences: A phase 2 trial.
   Radiother Oncol. 2026;220:111538.
   PubMed     Abstract available
   
   
   May 2026
10. HOGSBJERG KW, Thomsen MS, Maae E, Mjaaland I, et al
    Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1.
    Radiother Oncol. 2026 May 13:111594. doi: 10.1016/j.radonc.2026.111594.
    PubMed     Abstract available
    
    
    
11. MONTANARI J, Vinasco-Sandoval T, Lemaitre G, Vogin G, et al
    Non-coding (nc) RNAs and breast cancer treatment related sequelae: Current evidence and perspectives.
    Radiother Oncol. 2026 May 10:111570. doi: 10.1016/j.radonc.2026.111570.
    PubMed     Abstract available
    
    
    April 2026
12. RAVINDRA S, Cafferty FH, Harris E, Gulliford S, et al
    Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.
    Radiother Oncol. 2026 Apr 29:111547. doi: 10.1016/j.radonc.2026.111547.
    PubMed     Abstract available
    
    
    
13. ARRIGO A, Brants L, Kramp L, Vanreusel V, et al
    FLASH radiotherapy induces unique immunotranscriptomic profiles compared to conventional dose-rate radiotherapy, despite identical immune infiltration and antitumor efficacy in a murine model of triple-negative breast cancer.
    Radiother Oncol. 2026 Apr 28:111548. doi: 10.1016/j.radonc.2026.111548.
    PubMed     Abstract available
    
    
    
14. RUSSELL NS, Dixon MJ, Sainsbury R, Chua B, et al
    Response to Machiels et al. reconsidering the role of PMRT in low to intermediate risk breast cancer: applying results from previous standards of treatments in the current multimodal practice, FRC.
    Radiother Oncol. 2026 Apr 20:111542. doi: 10.1016/j.radonc.2026.111542.
    PubMed    
    
    
    
15. BECHERINI C, Blondeaux E, Delucchi V, Visani L, et al
    Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.
    Radiother Oncol. 2026;219:111523.
    PubMed     Abstract available
    
    
    March 2026
16. CANHA-BORGES A, Nunes B, Estevao D, Fernandes R, et al
    Radiotherapy induces layer-specific molecular and ultrastructural alterations in triple-negative breast cancer spheroids.
    Radiother Oncol. 2026 Mar 30:111518. doi: 10.1016/j.radonc.2026.111518.
    PubMed     Abstract available
    
    
    February 2026
17. SHAH I, Lucas S, Walsh R, Osman I, et al
    Artificial intelligence model for cardiovascular disease risk prediction in breast cancer patients using electronic health records and computed tomography scans.
    Radiother Oncol. 2026 Feb 25:111455. doi: 10.1016/j.radonc.2026.111455.
    PubMed     Abstract available
    
    
    
18. ALKNER S, Appelgren M, Szulkin R, Wieslander E, et al
    Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC.
    Radiother Oncol. 2026;218:111454.
    PubMed     Abstract available
    
    
    
19. MACHIELS M, Kaidar-Person O, Marta GN, Meattini I, et al
    Reconsidering the role of PMRT in low to intermediate risk breast cancer: Applying results from previous standards of treatment in the current multimodal practice.
    Radiother Oncol. 2026;217:111416.
    PubMed     Abstract available
    
    
    January 2026
20. MINK VAN DER MOLEN DR, Batenburg MCT, van 't Westeinde T, Houweling AC, et al
    Acute toxicity and quality of life after 5-fraction versus 15-fraction adjuvant radiotherapy following conventional or oncoplastic breast-conserving surgery - a real-world prospective cohort study.
    Radiother Oncol. 2026;214:111310.
    PubMed     Abstract available
    
    
    
21. SALVESTRINI V, Marrazzo L, Barletta G, Becherini C, et al
    Cardiac safety of ultra-hypofractionated whole breast irradiation: Results from the SAFE-FORWARD observational prospective cohort study.
    Radiother Oncol. 2026;214:111267.
    PubMed     Abstract available
    
    
    
22. HOVENIER R, Huele EH, Bindels BJJ, van Oss A, et al
    Pain response of patients treated with radiotherapy for painful bone metastases between 2013 and 2024 - An analysis of the prospective real-world PRESENT cohort.
    Radiother Oncol. 2026;214:111263.
    PubMed     Abstract available
    
    
    
23. BRION T, Balde M, Allodji R, Rossier C, et al
    Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial.
    Radiother Oncol. 2026;214:111202.
    PubMed     Abstract available
    
    
    
24. LICHTER KE, Asaro A, Qureshi MM, Truong MT, et al
    The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation.
    Radiother Oncol. 2026;214:111161.
    PubMed     Abstract available
    
    
    
25. JAIKUNA T, Wilson F, Anandadas C, Azria D, et al
    Unveiling regions associated with acute and late breast side-effects from breast radiotherapy using voxel-wise image-based data mining analysis.
    Radiother Oncol. 2026;214:111230.
    PubMed     Abstract available
    
    
    
26. ATTILI A, Algranati C, Cianchetti M, Giacomelli I, et al
    A dedicated MKM-based radiobiological model for secondary cancer estimation in charged particle radiotherapy: An application in lymphomas and breast proton therapy.
    Radiother Oncol. 2026;214:111229.
    PubMed     Abstract available
    
    
    December 2025
27. MALONE C, Ryan S, Nicholson J, Brennan S, et al
    From rugged ridges to radiotherapy ROIs: Translating topographical metrics to Surface-Guided Radiation Therapy regions of Interest in radiotherapy.
    Radiother Oncol. 2025;213:111173.
    PubMed     Abstract available
    
    
    November 2025
28. NG S, Kirby AM, Kilburn LS, Griffin C, et al
    Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5?years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials.
    Radiother Oncol. 2025 Nov 27:111301. doi: 10.1016/j.radonc.2025.111301.
    PubMed     Abstract available
    
    
    
29. THOMSEN MS, Offersen BV
    Response to comment on "Quality assessment of 2705 treatment plans in the randomised Danish breast cancer Group Skagen trial 1".
    Radiother Oncol. 2025 Nov 19:111286. doi: 10.1016/j.radonc.2025.111286.
    PubMed    
    
    
    
30. GAO C, Wang L, Ma K, Chen Y, et al
    Comment on "Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1".
    Radiother Oncol. 2025 Nov 14:111285. doi: 10.1016/j.radonc.2025.111285.
    PubMed    
    
    
    
31. BILSKI M, Kuncman L, Orzechowska M, Cisek P, et al
    Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study.
    Radiother Oncol. 2025;214:111280.
    PubMed     Abstract available
    
    
    October 2025
32. ZAMAGNI A, Luis AM, Mjaaland I, Chirila ME, et al
    ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives.
    Radiother Oncol. 2025 Oct 27:111236. doi: 10.1016/j.radonc.2025.111236.
    PubMed     Abstract available
    
    
    
33. BELARDO A, Dimayuga KB, Perna L, Fodor A, et al
    Density and volume of cardiac calcifications detected on planning CT predicts cardiotoxicity after hypo-fractionated whole breast Radiotherapy.
    Radiother Oncol. 2025;211:111098.
    PubMed     Abstract available
    
    
    
34. NG S, Kilburn LS, Kirby AM, Griffin C, et al
    Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial.
    Radiother Oncol. 2025;211:111056.
    PubMed     Abstract available
    
    
    September 2025
35. JOSEPH K, Ademola A, Zebak J, Singh A, et al
    Adjuvant radiotherapy alone, an effective treatment option for early-stage low- risk breast cancer in women over 50: results from a population based cohort study using a Canadian provincial database.
    Radiother Oncol. 2025 Sep 29:111175. doi: 10.1016/j.radonc.2025.111175.
    PubMed     Abstract available
    
    
    
36. THOMSEN MS, Lorenzen EL, Alsner J, Krogh SL, et al
    Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1.
    Radiother Oncol. 2025 Sep 15:111142. doi: 10.1016/j.radonc.2025.111142.
    PubMed     Abstract available
    
    
    
37. WANG DQ, Yan L, Wu HF, Zhong YH, et al
    Prospective cohort study to validate esophageal dose constraints and predictive models for esophagitis in patients with breast cancer undergoing hypofractionated regional nodal radiotherapy.
    Radiother Oncol. 2025;212:111120.
    PubMed     Abstract available
    
    
    August 2025
38. OLIVEROS S, Goyal A, Dodwell D
    The impact of radiotherapy on trials of axillary management in early breast cancer.
    Radiother Oncol. 2025 Aug 6:111054. doi: 10.1016/j.radonc.2025.111054.
    PubMed     Abstract available
    
    
    
39. NELISSEN SH, Young-Afat DA, Bongard HJGDVD, Coert JH, et al
    Neoadjuvant radiotherapy and immediate breast reconstruction: A systematic review of literature of the last decade.
    Radiother Oncol. 2025;209:110991.
    PubMed     Abstract available
    
    
    
40. KAIDAR-PERSON O, Poortmans P, Meattini I, Tramm T, et al
    An additional peril of pathologic complete response.
    Radiother Oncol. 2025;209:110962.
    PubMed     Abstract available
    
    
    
41. HORBERGER F, Petersson K, Ceberg S, Back S, et al
    Investigating the therapeutic potential of FLASH radiotherapy - a treatment planning study.
    Radiother Oncol. 2025;209:110947.
    PubMed     Abstract available
    
    
    July 2025
42. PUTORA PM, Henke G, Bese N, Boersma L, et al
    What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy?
    Radiother Oncol. 2025 Jul 20:111055. doi: 10.1016/j.radonc.2025.111055.
    PubMed     Abstract available
    
    
    
43. BOERSMA LJ, Hessels A, Roberti S, Seravall E, et al
    Selection of patients for proton therapy to reduce risk of second primary lung and breast cancer.
    Radiother Oncol. 2025 Jul 4:110998. doi: 10.1016/j.radonc.2025.110998.
    PubMed     Abstract available
    
    
    
44. GUCKENBERGER M, Wilke L, Billiet C, Rogers S, et al
    Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trial.
    Radiother Oncol. 2025;208:110940.
    PubMed     Abstract available
    
    
    June 2025
45. BRUNT AM, Cafferty FH, Wheatley D, Sydenham MA, et al
    Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.
    Radiother Oncol. 2025;207:110915.
    PubMed     Abstract available
    
    
    
46. NIELSEN AWM, Thorsen LBJ, Ozcan D, Matthiessen LW, et al
    Local recurrence with and without a tumour-bed boost: A post-hoc analysis of the DBCG IMN2 study.
    Radiother Oncol. 2025;207:110905.
    PubMed     Abstract available
    
    
    May 2025
47. PRADES-SAGARRA E, Geurts FAP, Biemans R, Lieuwes NG, et al
    The radiosensitizing effect of Caffeic Acid Phenethyl Ester in breast cancer is dependent on p53 status.
    Radiother Oncol. 2025;209:110945.
    PubMed     Abstract available
    
    
    
48. KIM S, Jeon SH, Kim Y, Park N, et al
    TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model.
    Radiother Oncol. 2025 May 11:110932. doi: 10.1016/j.radonc.2025.110932.
    PubMed     Abstract available
    
    
    
49. CALUWE A, Bellal S, Cao K, Peignaux K, et al
    Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.
    Radiother Oncol. 2025;206:110836.
    PubMed     Abstract available
    
    
    March 2025
50. BRION T, Ghodssighassemabadi R, Auzac G, Kirova Y, et al
    Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial.
    Radiother Oncol. 2025;207:110849.
    PubMed     Abstract available
    
    
    
51. VINCENZI MM, Cicchetti A, Castriconi R, Mangili P, et al
    Training and temporally validating an NTCP model of acute toxicity after whole breast radiotherapy, including the impact of advanced delivery techniques.
    Radiother Oncol. 2025;204:110700.
    PubMed     Abstract available
    
    
    February 2025
52. BYUN HK, Kim H, Son J, Cho Y, et al
    Impact of bra application in breast cancer radiotherapy: A pilot prospective randomized trial.
    Radiother Oncol. 2025;206:110785.
    PubMed     Abstract available
    
    
    January 2025
53. CHUFAL KS, Ahmad I, Miller AA, Bajpai R, et al
    Machine learning model for predicting DIBH non-eligibility in left-sided breast cancer radiotherapy: Development, validation and clinical impact analysis.
    Radiother Oncol. 2025;205:110764.
    PubMed     Abstract available
    
    
    
54. EOM A, Kirkwood D, Pond G, Hodgson N, et al
    Radiation therapy and immigration status in women with breast cancer.
    Radiother Oncol. 2025 Jan 31:110774. doi: 10.1016/j.radonc.2025.110774.
    PubMed     Abstract available
    
    
    
55. YEH J, Tacey M, Harris B, Lau E, et al
    Stabilised hyaluronic acid gel marker versus surgical clips for tumour bed delineation in breast cancer radiotherapy using MRI-simulation.
    Radiother Oncol. 2025;205:110749.
    PubMed     Abstract available
    
    
    
56. MOSHE N, Haisraely O, Globus O, Faermann R, et al
    Breast cancer outcomes after skin- and nipple-sparing mastectomy in BRCA pathogenic mutation carriers versus non-BRCA carriers.
    Radiother Oncol. 2025;205:110710.
    PubMed     Abstract available
    
    
    
57. REFSGAARD L, Buhl ES, Nielsen AWM, Thomsen MS, et al
    Quality assurance of internal mammary node irradiation in the DBCG IMN2 study.
    Radiother Oncol. 2025;202:110600.
    PubMed     Abstract available
    
    
    
58. CHUNG CV, Khan MS, Olanrewaju A, Pham M, et al
    Knowledge-based planning for fully automated radiation therapy treatment planning of 10 different cancer sites.
    Radiother Oncol. 2025;202:110609.
    PubMed     Abstract available
    
    
    December 2024
59. REFSGAARD L, Holm Milo ML, Buhl ES, Jensen JM, et al
    The effect of coronary artery calcifications and radiotherapy on the risk of coronary artery disease in high-risk breast cancer patients in the DBCG RT-Nation cohort.
    Radiother Oncol. 2024 Dec 24:110705. doi: 10.1016/j.radonc.2024.110705.
    PubMed     Abstract available
    
    
    
60. LATORRE-MUSOLL A, Oses G, Antelo G, Serrano-Rueda S, et al
    Transit-guided radiation therapy: a novel patient monitoring approach.
    Radiother Oncol. 2024;201:110580.
    PubMed     Abstract available
    
    
    
61. THOMSEN MS, Alsner J, Lutz CM, Berg M, et al
    Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost.
    Radiother Oncol. 2024;201:110574.
    PubMed     Abstract available
    
    
    
62. GUINOT JL, Gutierrez-Miguelez C, Meszaros N, Gonzalez-Perez V, et al
    Five-year results of the very accelerated partial breast irradiation VAPBI phase I-II GEC-ESTRO trial.
    Radiother Oncol. 2024;201:110543.
    PubMed     Abstract available
    
    
    November 2024
63. KUBECZKO M, Gabrys D, Rembak-Szynkiewicz J, Graupner D, et al
    Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.
    Radiother Oncol. 2024 Nov 18:110639. doi: 10.1016/j.radonc.2024.110639.
    PubMed     Abstract available
    
    
    
64. BUHL ES, Refsgaard LH, Al-Rawi SA, Andersen K, et al
    Population based audit of heart radiation doses in 6925 high-risk breast cancer patients from the Danish breast cancer group RT Nation study.
    Radiother Oncol. 2024 Nov 16:110643. doi: 10.1016/j.radonc.2024.110643.
    PubMed     Abstract available
    
    
    
65. VAN SCHIE P, Huisman RG, Wiersma T, Knegjens JL, et al
    Local control and toxicity after stereotactic radiotherapy in brain metastases patients and the impact of novel systemic treatments.
    Radiother Oncol. 2024;200:110540.
    PubMed     Abstract available
    
    
    
66. BOUTRY C, Moreau NN, Jaudet C, Lechippey L, et al
    Machine learning and deep learning prediction of patient specific quality assurance in breast IMRT radiotherapy plans using Halcyon specific complexity indices.
    Radiother Oncol. 2024;200:110483.
    PubMed     Abstract available
    
    
    
67. SMINE Z, Poeta S, De Caluwe A, Desmet A, et al
    Automated segmentation in planning-CT for breast cancer radiotherapy: A review of recent advances.
    Radiother Oncol. 2024;202:110615.
    PubMed     Abstract available
    
    
    October 2024
68. DE ROSE F, Carmen De Santis M, Lucidi S, Ray Colciago R, et al
    Dose constraints in breast cancer radiotherapy. A critical review.
    Radiother Oncol. 2024 Oct 18:110591. doi: 10.1016/j.radonc.2024.110591.
    PubMed     Abstract available
    
    
    
69. KAIDAR-PERSON O, Ratosa I, Franco P, Masiello V, et al
    The Assisi think tank focus review on postoperative radiation for lobular breast cancer.
    Radiother Oncol. 2024 Oct 10:110573. doi: 10.1016/j.radonc.2024.110573.
    PubMed     Abstract available
    
    
    
70. BUHL ES, Lorenzen EL, Refsgaard L, Nielsen AWM, et al
    Development and comprehensive evaluation of a national DBCG consensus-based auto-segmentation model for lymph node levels in breast cancer radiotherapy.
    Radiother Oncol. 2024;201:110567.
    PubMed     Abstract available
    
    
    
71. ALI T, Vellengara M, Albalushi FY, Basheer R, et al
    Deep Inspiration breath Hold facilitates surgical cavity registration on cone beam imaging for Partial breast irradiation.
    Radiother Oncol. 2024;199:110471.
    PubMed     Abstract available
    
    
    
72. ALONGI F, Nicosia L, Ricardi U, Scorsetti M, et al
    Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E(2)-RADIatE OligoCare cohort.
    Radiother Oncol. 2024;199:110466.
    PubMed     Abstract available
    
    
    
73. JOHNSON PB, Mamalui M, Brodin P, Janssens G, et al
    Secondary cancer risk in six anatomical sites when using PAT, IMPT, and VMAT/IMRT radiotherapy.
    Radiother Oncol. 2024;199:110421.
    PubMed     Abstract available
    
    
    September 2024
74. KAIDAR-PERSON O, Boersma L, De Brouwer P, Weltens C, et al
    The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies.
    Radiother Oncol. 2024 Sep 26:110563. doi: 10.1016/j.radonc.2024.110563.
    PubMed     Abstract available
    
    
    
75. GROOT KOERKAMP M, Stijnman P, Houweling A, Zachiu C, et al
    Automated dose evaluation on daily cone-beam computed tomography for breast cancer patients.
    Radiother Oncol. 2024;200:110541.
    PubMed     Abstract available
    
    
    August 2024
76. LAVIGNE D, Hijal T, Vavassis P, Guilbert MC, et al
    Single preoperative radiation therapy with delayed surgery for low-risk breast cancer: Oncologic outcome, toxicity and cosmesis of the SPORT-DS phase I trial.
    Radiother Oncol. 2024;200:110515.
    PubMed     Abstract available
    
    
    
77. MAHMOUD D, Yassa M, Alvarado L, Lambert C, et al
    Single pre-operative radiation therapy (SPORT-CK) trial for low-risk breast cancer: Early results of a phase 2 study.
    Radiother Oncol. 2024;200:110510.
    PubMed     Abstract available
    
    
    
78. KIM Y, Jeon SH, Kim S, Kang MH, et al
    In vitro-irradiated cancer vaccine enhances anti-tumor efficacy of radiotherapy and PD-L1 blockade in a syngeneic murine breast cancer model.
    Radiother Oncol. 2024;200:110480.
    PubMed     Abstract available
    
    
    
79. ALKNER S, Wieslander E, Lundstedt D, Berg M, et al
    Quality assessment of radiotherapy in the prospective randomized SENOMAC trial.
    Radiother Oncol. 2024;197:110372.
    PubMed     Abstract available
    
    
    
80. FRANCESCHINI D, Teriaca MA, Mancosu P, Bertolini A, et al
    Prospective phase II trial on ablative stereotactic body radiation therapy (SBRT) for medically inoperable thoracic nodes metastases.
    Radiother Oncol. 2024;197:110335.
    PubMed     Abstract available
    
    
    July 2024
81. CHUN SJ, Kim K, Kim YB, Paek SH, et al
    Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery.
    Radiother Oncol. 2024;199:110461.
    PubMed     Abstract available
    
    
    
82. BOERSMA LJ, Bijker N, Stam MR
    Reporting breast cancer radiation therapy details in studies and daily practice: Nice-to-have or a must-have?
    Radiother Oncol. 2024 Jul 17:110429. doi: 10.1016/j.radonc.2024.110429.
    PubMed    
    
    
    
83. OVERGAARD J, Ccm Hulshof M, Dahl O, Arcangeli G, et al
    ESHO 1-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of locally advanced breast carcinoma. A randomized multicenter study by the European Society for Hyperthermic Oncology.
    Radiother Oncol. 2024;196:110313.
    PubMed     Abstract available
    
    
    June 2024
84. SONG YC, Chen SY, Zhao XR, Jing H, et al
    Prognostic value of lymphocytes in patients with breast cancer receiving radiotherapy after breast-conserving surgery: A post hoc analysis of a phase III randomized trial.
    Radiother Oncol. 2024 Jun 17:110390. doi: 10.1016/j.radonc.2024.110390.
    PubMed     Abstract available
    
    
    
85. CACHO-DIAZ B, Valdes-Ferrer SI, Chavez-MacGregor M, Salmeron-Moreno K, et al
    Brain metastasis risk prediction model in females with hormone receptor-positive breast cancer.
    Radiother Oncol. 2024 Jun 9:110379. doi: 10.1016/j.radonc.2024.110379.
    PubMed     Abstract available
    
    
    
86. CHRIST SM, Alongi F, Ricardi U, Scorsetti M, et al
    Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E(2)-RADIatE OligoCare study.
    Radiother Oncol. 2024;195:110235.
    PubMed     Abstract available
    
    
    May 2024
87. HOGSBJERG KW, Offersen BV
    Author's response to Letter-to-the-Editor from Chang JS. concerning: "Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial".
    Radiother Oncol. 2024;197:110351.
    PubMed     Abstract available
    
    
    
88. CHEN F, Zhou P, Ren G, Lee EKW, et al
    Interpretable deep learning insights: Unveiling the role of 1 Gy volume on lymphopenia after radiotherapy in breast cancer.
    Radiother Oncol. 2024;197:110333.
    PubMed     Abstract available
    
    
    
89. HANNOUN-LEVI JM, Gimeno Morales M, Gal J, Anchuelo J, et al
    Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort.
    Radiother Oncol. 2024;194:110217.
    PubMed     Abstract available
    
    
    
90. CICCHETTI A, Mangili P, Fodor A, Gabellini MGU, et al
    Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy.
    Radiother Oncol. 2024;194:110183.
    PubMed     Abstract available
    
    
    April 2024
91. REFSGAARD L, Skarso Buhl E, Yates E, Maae E, et al
    Evaluating Danish Breast Cancer Group locoregional radiotherapy guideline adherence in clinical treatment data 2008-2016: The DBCG RT Nation study.
    Radiother Oncol. 2024 Apr 25:110289. doi: 10.1016/j.radonc.2024.110289.
    PubMed     Abstract available
    
    
    March 2024
92. FRANCESCHINI D, Franzese C, Comito T, Ilieva MB, et al
    Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer.
    Radiother Oncol. 2024;195:110240.
    PubMed     Abstract available
    
    
    
93. HUIJSKENS S, Granton P, Fremeijer K, van Wanrooij C, et al
    Clinical practicality and patient performance for surface-guided automated VMAT gating for DIBH breast cancer radiotherapy.
    Radiother Oncol. 2024 Mar 14:110229. doi: 10.1016/j.radonc.2024.110229.
    PubMed     Abstract available
    
    
    
94. KUBECZKO M, Jarzab M, Gabrys D, Krzywon A, et al
    Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].
    Radiother Oncol. 2024;194:110188.
    PubMed    
    
    
    
95. HOGSBJERG KW, Maae E, Nielsen MH, Stenbygaard L, et al
    Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial.
    Radiother Oncol. 2024 Mar 3:110195. doi: 10.1016/j.radonc.2024.110195.
    PubMed     Abstract available
    
    
    
96. GIMENO-MORALES M, Martinez-Monge R, Martinez-Lage A, Jablonska PA, et al
    Long-term results of intraoperative multicatheter breast implant (IOMBI) for accelerated partial breast irradiation (APBI) on early breast cancer patients.
    Radiother Oncol. 2024;194:110193.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum